吉西他滨联合康莱特治疗晚期胰腺癌的临床疗效研究
马守成;赵达;侯小明;袁芳芸
【期刊名称】《现代肿瘤医学》 【年(卷),期】2012(020)007
【摘要】Objective; To study the clinical effect of combination treatment with gemcitabine (GEM) and Kanglaite injection on advanced pancreatic cancer. Methods: In this randomized controlled study, to select 64 cases of advanced pancreatic cancer during Jul.2002 to Sep.2008.which included gemcitabine chemotherapy 32 cases (group A),gemcitabine + Kanglaite 32 cases (group B). Results;The rates of clinical benefit response on the 3rd month,the difference of group GEM + Kanglaite injection compared with GEM was not significant ( P > 0. 05 ) ; on the 6th month, group B was higher than group GEM (P < 0. 05). The rates of objective tumor response difference between group B and A was not significant (P>0.05) ,but there was difference in clinical benefit response rate ( P < 0.05) , and adverse events (P<0.05). Conclusion;Treatment of pancreatic cancer with gemcitabine chemotherapy combined Kanglaite injection improved the clinical benefit response side - effect quality of life of advanced pancreatic cancer.%目的:探讨吉西他滨(GEM)联合康莱特治疗晚期胰腺癌的临床疗效.方法:对我院肿瘤治疗中心2002年7月至2008年9月间收治的64例晚期胰腺癌患者进行随机对照研究.32例GEM化疗病人归为A组,32例GEM化疗+康莱特治疗病人归为B组.结果:GEM组和GEM+康莱特
组的临床受益率第3周期时差异无统计学意义(P＞0.05)；第6周期时GEM+康莱特组显著高于GEM组,差异有统计学意义(P＜0.05).GEM+康莱特组与GEM组近期有效率差异无统计学意义(P＞0.05),但可提高总临床获益率(P＜0.05),且不良反应差异有统计学意义(P＜0.05).结论:康莱特联合吉西他滨治疗晚期胰腺癌可提高患者临床受益反应率和总临床获益率,降低化疗不良反应,提高生存质量.
【总页数】3页(1415-1417)
【关键词】胰腺癌;吉西他滨;康莱特;治疗 【作者】马守成;赵达;侯小明;袁芳芸
【作者单位】兰州大学第一医院肿瘤内科,甘肃兰州730000;兰州大学第一医院肿瘤内科,甘肃兰州730000;兰州大学第一医院肿瘤内科,甘肃兰州730000;兰州大学第一医院肿瘤内科,甘肃兰州730000 【正文语种】中文 【中图分类】R735.9 【文献来源】
https://www.zhangqiaokeyan.com/academic-journal-cn_journal-modern-oncology_thesis/0201236442273.html 【相关文献】
1.康莱特联合吉西他滨治疗进展期胰腺癌的疗效观察 [J], 黄超
2.康莱特注射液联合吉西他滨注射液和替吉奥胶囊治疗晚期胰腺癌的临床研究 [J], 张新峰; 乔翠霞; 程旭锋; 刘琦; 高启龙; 杨旭初; 王怀璋
3.吉西他滨和5一氟尿嘧啶联合治疗晚期胰腺癌的疗效分析 [J], 孙利人; 张少
丽; 何月玲
4.三维适形放射联合吉西他滨治疗晚期胰腺癌临床疗效分析 [J], 王磊
5.吉西他滨联合顺铂或氟尿嘧啶治疗晚期胰腺癌临床疗效的比较 [J], 束永前; 刘凌翔; 黄普文; 卢凯华; 殷咏梅
以上内容为文献基本信息，获取文献全文请下载
吉西他滨联合康莱特治疗晚期胰腺癌的临床疗效研究
